Welcome to EAPforCF.com

Learn more about the Aztreonam Lysine for Inhalation EAP

This EAP Research Study is intended to make the investigational (experimental) formulation of aztreonam lysine for inhalation available to people with cystic fibrosis and Pseudomonas aeruginosa in their lungs, who have limited or no treatment options, and who are at risk for disease progression. To enroll, you or your loved one must be screened by a participating doctor and meet certain eligibility criteria. Program participants will receive aztreonam lysine for inhalation and the eFlow^® Electronic Nebulizer at no cost while participating in this EAP. To see if you or your loved one may be eligible, click here.

Aztreonam lysine for inhalation is currently being studied in Phase III clinical trials, and has not been determined to be safe or effective in humans by the U.S. Food and Drug Administration (FDA). There is no guarantee that aztreonam lysine for inhalation will help you or your loved one. Your condition may not get better or may become worse during this research study. Participation in this research study is restricted to treatment centers in the United States only.